US SEC Trading Suspension Halt Orders — October 29, 2026

Nasdaq Hearings Panel determined to delist; closing bid was $0.87 on October 14, 2026, below the $1.00 exception threshold, and trading is suspended at the open on October 30, 2026 — a definitive liquidity event for current holders

Nasdaq minimum bid price notice received October 23, 2026; delisting effective November 2, 2026 unless the company appeals by October 30, 2026 — binary near-term outcome with appeal stay potential

Ineligible for the standard 180-day compliance period because it already effected a reverse split within the prior year, signaling prior listing distress and limiting remediation options

Audit committee deficiency under Rule 5605(c)(2)(A) cured on October 27, 2026 with the appointment of independent director Melanie Furlan, joining Scott Wollney and Carol Craig — partial de-risking of the Nasdaq listing

Majority independent director deficiency under Rule 5605(b)(1) remains outstanding following Roderick McIllree's October 20, 2026 resignation; cure period extends to the earlier of the next annual meeting or October 20, 2027

Voluntary transfer of common and 4.450% Series B preferred depositary shares from NYSE to TXSE, retaining symbols CFR and CFR.PrB; NYSE trading ends November 11, 2026 and TXSE begins November 12, 2026 — no fundamental change to the business [NEUTRAL/BULLISH]

Board-authorized exchange transfer is explicitly not a delisting for failure to meet listing standards, distinguishing it from the Nasdaq compliance failures in the same stream

Company states there is no immediate effect on its Nasdaq listing, with common stock (GLND) and warrants (GLNDW) continuing to trade on the Nasdaq Global Market

Company intends to apply for quotation on the OTC Markets OTCID tier upon suspension, but provides no assurance of that transition — potential liquidity degradation for holders

Three of four filings are negative-sentiment listing-compliance events, versus one neutral voluntary transfer, indicating a risk-off micro-cap listing environment in this period

Nasdaq Hearings Panel exception was conditioned on maintaining a closing bid price of at least $1.00 for each trading day through November 9, 2026; the $0.87 close on October 14, 2026 breached that condition and triggered delisting

Trading suspension at the open on October 30, 2026 and expected Form 25 filing to delist and deregister under Section 12(b) — immediate loss of exchange liquidity and reduced institutional eligibility

Delisting effective November 2, 2026 absent an appeal by October 30, 2026; the appeal deadline is the binding near-term risk event

Company acknowledges delisting would reduce liquidity, shrink its investor base, limit access to public capital markets, and impair its ability to grant equity incentives

Prior reverse stock split within the last year makes the company ineligible for the standard 180-day cure period, reflecting a history of bid-price non-compliance

Majority independent director deficiency remains outstanding after McIllree's resignation; failure to cure by the applicable deadline could result in a Nasdaq delisting determination

Cure period is tied to the next annual shareholders' meeting; if the meeting is held before April 19, 2027, compliance must be evidenced by April 19, 2027, creating a hard deadline

NYSE-to-TXSE transfer introduces execution and liquidity-transition risk around November 11-12, 2026, including potential index-membership and investor-mandate implications

Micro-cap biotech names (Propanc, Glucotrack) are disproportionately exposed to $1.00 bid-price delisting mechanics, a structural overhang for the sector

Appeal by October 30, 2026 would stay the delisting pending the Panel's decision, creating a binary catalyst window for event-driven traders

Company believes it has cured the deficiency; if the Panel accepts that view, the stock could avoid delisting and re-rate from distressed levels

Planned OTCID quotation provides a potential post-suspension trading venue; however, no assurance is provided, so this is a high-risk liquidity event rather than a clean opportunity

Audit committee cure on October 27, 2026 removes one of two Nasdaq deficiencies; resolution of the majority-independent-director issue would fully de-risk the listing

Common stock and warrants (GLND, GLNDW) continue trading on the Nasdaq Global Market with no immediate effect, preserving liquidity during the cure period

TXSE listing beginning November 12, 2026 under the same symbols (CFR, CFR.PrB) may attract Texas-focused and regional-exchange flows; the voluntary nature signals confidence in the transfer

The 4.450% Series B preferred depositary shares transfer alongside the common, preserving the income vehicle for preferred holders through the exchange change

Board-authorized transfer is a strategic, not distress-driven, event — any NYSE-exit-related selling pressure around November 11 could create an entry point for long-term holders

Distressed micro-cap delisting names may attract specialist OTC/market-making interest as they migrate to OTCID or alternative venues

Two of four filings (Propanc, Glucotrack) are $1.00 minimum bid price failures under Nasdaq Rule 5550(a)(2), both with prior reverse splits, highlighting structural pressure on sub-$1 micro-caps

Propanc's prior reverse split within one year disqualified it from the standard 180-day cure period under Rule 5810(c)(3)(A)(iv), a recurring trap for serial reverse-splitters

Greenland Energy's dual deficiencies under Rules 5605(b)(1) and 5605(c)(2)(A) show board-composition compliance is an active listing-risk vector, though the audit committee cure was swift [NEUTRAL/RISK THEME]

Cullen/Frost's voluntary NYSE-to-TXSE transfer is an early example of a large-cap bank choosing a regional exchange, potentially foreshadowing broader listing-venue competition

Glucotrack's planned OTCID application reflects the standard fallback path for delisted micro-caps, though lack of assurance underscores the fragility of OTC transitions

The stream clusters hard dates — October 30 (Glucotrack suspension, Propanc appeal deadline), November 2 (Propanc delisting effective), November 11-12 (Cullen/Frost transition) — creating a dense catalyst window

Appeal deadline October 30, 2026 — filing an appeal stays delisting pending Panel decision; failure to appeal triggers delisting effective November 2, 2026

Trading suspension at the open on October 30, 2026; watch for Form 25 filing and any OTCID application update

Majority independent director deficiency cure — monitor board appointments ahead of the next annual meeting; compliance must be evidenced by April 19, 2027 if the meeting is held before that date

NYSE trading ends at market close November 11, 2026; TXSE trading begins at market open November 12, 2026 — watch for liquidity and index-membership effects

Series B preferred depositary shares transfer to TXSE alongside common; monitor preferred pricing around the transition

Watch for any Propanc appeal decision and Glucotrack Form 25 confirmation

Watch for any additional 8-K disclosures on board composition or Nasdaq correspondence

Monitor for follow-on delisting notices among micro-caps with recent reverse splits as the $1.00 bid rule continues to bite